Key result
Recombinant VP1 of FMDV induced apoptosis in BHK-21 and cancer cell lines (MCF-7, PC-3) by modulating the Akt signaling pathway.
Why the study?
Does recombinant VP1 of FMDV induce apoptosis in cancer cells?
Does recombinant VP1 of FMDV induce apoptosis in cancer cells?
Recombinant VP1 of FMDV induces apoptosis in cancer cells via the Akt signaling pathway, suggesting its potential utility as a targeted apoptotic agent for human cancer.
Does not support clinical use in oncology; hypothesis-generating for Akt-targeted apoptosis induction pending in vivo validation.
Foot-and-mouth disease virus (FMDV) binds to cellular integrins through an RGD motif in its capsid protein, VP1. It is unclear, however, what kind of cellular event(s) are triggered after the binding of VP1 to the cells. In this study, we show that aqueous soluble recombinant DNA-derived VP1 (rVP1) of FMDV induced apoptosis of BHK-21 cells after binding to integrins. In addition, treatment of BHK-21 cells with rVP1 resulted in deactivation of Akt and enhancement of several proapoptotic responses such as dephosphorylation of glycogen synthase kinase-3beta and cleavage of procaspase-3, -7, and -9. Additional studies revealed that the rVP1 treatment caused apoptosis of cancer cells, including MCF-7 (a breast carcinoma cell line with a functional deletion of the caspase-3 gene) and PC-3 (a sphingosine 1-phosphate receptor subtype 3-deficient androgen-independent prostate cancer cell line). These results suggest that rVP1 of FMDV may be used selectively as a potent apoptotic agent for human cancer by modulating the Akt signaling pathway and that its effect is not primarily dependent on either activation of procaspase-3 or deactivation of sphingosine 1-phosphate receptor subtype 3.
No takes yet. Share an insight, caveat, or question.
Peng et al. (2004) studied Cancer. Recombinant DNA-derived VP1 (rVP1) of FMDV was evaluated on Apoptosis and deactivation of Akt. Recombinant VP1 of FMDV induced apoptosis in BHK-21 and cancer cell lines (MCF-7, PC-3) by modulating the Akt signaling pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: